
    
      Docetaxel and vinorelbine are well known active agents in the treatment of NSCLC. The
      standard treatment of elderly patients with advanced NSCLC is monotherapy with a third
      generation agent. The role of comprehensive geriatric assessment in treatment efficacy and
      tolerance is an area of investigation.
    
  